Overall survival and clinical characteristics of BRCA germline/somatic cholangiocarcinoma (CCA).

• DOI: 10.1200/jco.2016.34.4_suppl.244
• Publication Date: 2017-02-24T11:01:35Z
• Authors: Talia Golan; Maria Raitses-Gur...; Robin Kate Kelley; Andrea Grace Bocobo; Ayelet Borgida; Rachna T. Shroff; Spring Holter; Steven Gallinger; Maeve Aine Lowery; Ghassan K. Abou-Alfa; Daniel H. Ahn; Apurva Jain; Tanios S. Bekaii-...; Eitan Friedman; Milind M. Javle
• Keywords: Olaparib

244 Background: Biliary tract cancers (BTC) exhibit a diverse and high frequency of actionable mutations detectable using next generation sequencing (NGS). The Breast Cancer Linkage Consortium reported that BRCA2 mutation carriers are at increased risk for BTC with estimated relative 4.97, (95% CI = 1. 50-16.52). purpose this study was to evaluate the clinical characteristics germline/somatic BRCA1/2mutations in CCA patients. Methods: Multi-center retrospective analysis patients BRCA1/2- associated diagnosed between January 2000 December 2013. Cases were identified from databases participating institutions. Data including demographics, history, surgical procedures systemic chemotherapy or radiation extracted patient records. Results: Overall, we 18 cases 5 germline BRCA1/2 (4 BRCA2; 1 BRCA1) 13 harboring somatic (7 BRCA1; 6 BRCA2) NGS panel testing tumor 'actionable' mutations. One presented two different BRCA2gene. Mean age diagnosis 60 years (range 36-75), male: females (61.2% vs 38.8%, respectively). Stage diagnosis: I (n 4), II 3), III 3) IV 8). Six had extrahepatic CAA; twelve intrahepatic CCA. Prior therapy included platinum-based one receiving prior olaparib. Median overall survival stage I/II is 34.7 months CI, 7.06-62.9) stages III/IV 25 12.02-35.84). Conclusions: BRCA may have an enhanced therapeutic sensitivity DNA damaging agents. This needs confirmation larger cohort